Novel Hyperkalemia Drugs

Michael Naafs, A. B.

Department of Medicine, Naafs International Health Consultancy, Netherlands

Dr. Michael Naafs, A. B., Department of Medicine, Naafs International Health Consultancy, Netherlands.

Keywords: Hyperkalemia Drugs; Chronic Diseases; Pathophysiology

Abstract

In this mini-review pathophysiology, diagnosis and management of hyperkalemia are discussed with a special emphasis on the introduction of two novel potassium binders, patiromer and sodium zirconium cyclosilicate. These novel potassium binders enable patients to continue RAASi therapy in CHF, diabetes and CKD. Both have tested well as safe and efficacious and may result in a change in our therapeutic paradigm, by favouring their chronic use over discontinuation of RAASi treatment. Whether the effects of such a novel strategy translates to improved long-term clinical outcomes should be investigated in future trials.

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).